Effect of Gender on Outcomes After Cardiac Resynchronization Therapy in Patients With a Narrow QRS Complex: A Subgroup Analysis of the EchoCRT Trial

Background—In EchoCRT, a randomized controlled trial evaluating the effect of cardiac resynchronization therapy (CRT) in patients with a QRS duration of <130 ms and echocardiographic evidence of left ventricular dyssynchrony, the primary outcome (death from any cause or first hospitalization for worsening heart failure) occurred more frequently in the CRT-ON when compared with the control group. In this prespecified subgroup analysis, we evaluated the effect of sex on clinical outcome in EchoCRT. Methods and Results—In EchoCRT, 585 (72%) of included patients were men. At baseline, male patients had a higher incidence of ischemic cardiomyopathy and longer QRS duration. On uni- and multivariable analysis, no significant interaction was observed regarding sex for the primary or any of the secondary end points. Numerically, a higher all-cause mortality was observed in male patients randomized to CRT-ON versus CRT-OFF on univariable analysis (hazard ratio, 1.83; 95% confidence interval, 1.08–3.12); however, no statistically significant interaction compared with females randomized to CRT-ON versus CRT-OFF was noted (hazard ratio, 0.99; P interaction, 0.56). There was no difference in the primary safety end point of system-related complications, including CRT system- and implantation-related events. Conclusions—The largest hazard for all-cause mortality in EchoCRT was observed in men randomized to CRT-ON; the comparison with women did not reach statistical significance, which may be because of the premature termination of the trial and the limited data. These results suggest that male sex may be a risk factor for harm by CRT in patients with narrow QRS width, an observation which deserves further investigation. Clinical Trial Registration—URL: https://clinicaltrials.gov. Unique identifier: NCT00683696.

[1]  Anne L. Taylor Heart Failure in Women , 2015, Current Heart Failure Reports.

[2]  David G. Strauss,et al.  Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. , 2014, JAMA internal medicine.

[3]  F. Ruschitzka,et al.  Superresponse to Cardiac Resynchronization Therapy , 2014, Circulation.

[4]  P. Tchou,et al.  Probability and magnitude of response to cardiac resynchronization therapy according to QRS duration and gender in nonischemic cardiomyopathy and LBBB. , 2014, Heart rhythm.

[5]  Goldberger Jj,et al.  Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. , 2014 .

[6]  L. Fauchier,et al.  Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. , 2014, The New England journal of medicine.

[7]  J. Nielsen,et al.  ESC Guidelines on cardiac pacing and cardiac resynchronization therapy , 2014 .

[8]  Lluís Mont,et al.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.

[9]  S. Solomon,et al.  The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). , 2013, Journal of the American College of Cardiology.

[10]  Arthur J Moss,et al.  Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. , 2012, Journal of the American College of Cardiology.

[11]  L. Lund,et al.  Women have better long-term prognosis than men after cardiac resynchronization therapy. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  S. Solomon,et al.  Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. , 2011, Journal of the American College of Cardiology.

[13]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[14]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[15]  K. Dickstein,et al.  The European cardiac resynchronization therapy survey. , 2009, European heart journal.

[16]  P. Heidenreich,et al.  Gender Differences in Procedure-Related Adverse Events in Patients Receiving Implantable Cardioverter-Defibrillator Therapy , 2009, Circulation.

[17]  C. Klersy,et al.  Remission of left ventricular systolic dysfunction and of heart failure symptoms after cardiac resynchronization therapy: temporal pattern and clinical predictors. , 2008, American heart journal.

[18]  Nick Freemantle,et al.  Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge , 2007, European journal of heart failure.

[19]  D. Kass,et al.  Predictors of Sudden Cardiac Death and Appropriate Shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial , 2006, Circulation.

[20]  Lluís Mont,et al.  Predictors of lack of response to resynchronization therapy. , 2005, The American journal of cardiology.

[21]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[22]  J. Conti,et al.  Ventricular Reverse Remodeling and 6-Month Outcomes in Patients Receiving Cardiac Resynchronization Therapy: Analysis of the MIRACLE Study , 2005, Journal of Interventional Cardiac Electrophysiology.

[23]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[24]  A. Hall,et al.  Cell migration: Rho GTPases lead the way. , 2004, Developmental biology.

[25]  David O. Martin,et al.  Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. , 2002, JAMA.

[26]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[27]  R. Passman,et al.  Effects of Sex and Age on Electrocardiographic and Cardiac Electrophysiological Properties in Adults , 2001, Pacing and clinical electrophysiology : PACE.

[28]  P Kligfield,et al.  Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. , 1987, Circulation.